Clinical Trial Update: Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis [Phase 3]

View source ↗

Summary

This update reports the completion of a Phase 3 dose-titration study of sevelamer carbonate in patients with chronic kidney disease on hemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Renvela (sevelamer carbonate)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Chronic Kidney Disease, Chronic Kidney Disease on Hemodialysis | Phase 3 | Status: COMPLETED